Mechanism of Bicalutamide to Breast Cancer Cell Lines MDA-MB-453 and Inhibitory Effects of Its Combination with Everolimus

• Main Authors: ZHANG Yuqin, LU Yunfei, ZHANG Haitian
• Format: Article
• Language: zho
• Published: Magazine House of Cancer Research on Prevention and Treatment 2021-03-01
• Series: Zhongliu Fangzhi Yanjiu
• Subjects: bicalutamide; everolimus; breast cancer; drug combination
• Online Access: http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0819.htm
• ISSN: 1000-8578; 1000-8578

Objective To investigate the effect of bicalutamide on migration and invasion of androgen receptor(AR) positive breast cancer cells and related mechanism, and the effect of mTOR inhibitor everolimus combined with bicalutamide on the proliferation of MDA-MB-453 cells. Methods Western blot was used to detect the expression change of mTOR, p-mTOR and p-S6 in breast cancer cell lines before and after bicalutamide treatment. Transwell assay was used to detect the cell viability. MTT assay was used to detect the proliferation of MDA-MB-453 cells treated by the combination of bicalutamide and everolimus. The combined effect of the two drugs was calculated by Jin Zhengjun's method. Results After six days of bicalutamide treatment, the expression of mTOR, p-mTOR and p-S6 were decreased in MDA-MB-453 cells (Ρ =0.034, 0.05, 0.03). The invasion and migration were inhibited in MDA-MB-453 cells (migration: t =4.88, P =0.001, invasion: t =2.684, P =0.028). The proliferation of MDA-MB-453 cells was inhibited after the treatment of bicalutamide combined with everolimus, and the Q value were all greater than 1.15. Conclusion Bicalutamide could inhibit the invasion and migration of MDA-MB-453, and the inhibition effect is affected by the expression level of AR. The combination of bicalutamide and everolimus could synergistically inhibit the proliferation of AR positive breast cancer cells.